Alzheimer's disease: Pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents

ACS Chemical Neuroscience

Volumn 4, Issue 11, 2013, Pages 1417-1429

  Amiri, Houshang ^a   Saeidi, Kolsoum ^b   Borhani, Parvin ^b   Manafirad, Arash ^c   Ghavami, Mahdi ^c   Zerbi, Valerio ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

amyloid ; Magnetic resonance imaging; nanomedicine; nanotechnology; SPION

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PRESENILIN 1; PRESENILIN 2; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

AGING; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; BLOOD BRAIN BARRIER; CELL MIGRATION; CEREBROVASCULAR ACCIDENT; CHROMOSOME 1; CHROMOSOME 12; CHROMOSOME 21; DIABETES MELLITUS; DIETARY INTAKE; GENE; GENE MUTATION; GENETIC RISK; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESENILIN 1 GENE; PRESENILIN 2 GENE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; RISK FACTOR; SMOKING; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES;

EID: 84888382800     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn4001582     Document Type: Review

References (163)

1. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc. Natl. Acad. Sci. U.S.A. 82, 4245-4249
2. Selkoe, D. J. and Schenk, D. (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics Annu. Rev. Pharmacol. Toxicol. 43, 545-584
3. Mahmoudi, M. and Shokrgozar, M. A. (2012) Multifunctional stable fluorescent magnetic nanoparticles Chem. Commun. 48, 3957-3959
4. Mahmoudi, M. and Serpooshan, V. (2012) Silver-coated engineered magnetic nanoparticles are promising for the success in the fight against antibacterial resistance threat ACS Nano 6, 2656-2664
5. Helzner, E. P., Scarmeas, N., Cosentino, S., Tang, M. X., Schupf, N., and Stern, Y. (2008) Survival in Alzheimer disease: a multiethnic, population-based study of incident cases Neurology 71, 1489-1495
6. Xie, J., Brayne, C., Matthews, F. E., and Medical Research Council Cognitive, F., and Ageing Study, c. (2008) Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up BMJ 336, 258-262
7. Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J. Psychiatr. Res. 12, 189-198
8. Berger, G., Frolich, L., Weber, B., and Pantel, J. (2008) Diagnostic accuracy of the clock drawing test: the relevance of ″time setting'' in screening for dementia J. Geriatr. Psychiatry Neurol. 21, 250-260
9. Wilson, R. S., Arnold, S. E., Tang, Y., and Bennett, D. A. (2006) Odor identification and decline in different cognitive domains in old age Neuroepidemiology 26, 61-67
10. Mahmoudi, M. and Suslick, K. S. (2012) Protein fibrillation and the olfactory system: speculations on their linkage Trends Biotechnol. 30, 609-610
11. Van Dam, D. and De Deyn, P. P. (2006) Drug discovery in dementia: the role of rodent models Nat. Rev. Drug Discovery 5, 956-970
12. Allinson, T. M., Parkin, E. T., Turner, A. J., and Hooper, N. M. (2003) ADAMs family members as amyloid precursor protein alpha-secretases J. Neurosci. Res. 74, 342-352
13. Wisniewski, T. and Sigurdsson, E. M. (2010) Murine models of Alzheimer's disease and their use in developing immunotherapies Biochim. Biophys. Acta, Mol. Basis Dis. 1802, 847-859
14. Weller, R. O. and Nicoll, J. A. (2003) Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain Neurol. Res. 25, 611-616
15. Maat-Schieman, M., Roos, R., and van Duinen, S. (2005) Hereditary cerebral hemorrhage with amyloidosis-Dutch type Neuropathology 25, 288-297
16. Crawford, F., Suo, Z., Fang, C., and Mullan, M. (1998) Characteristics of the in vitro vasoactivity of beta-amyloid peptides Exp. Neurol. 150, 159-168
17. Niwa, K., Porter, V. A., Kazama, K., Cornfield, D., Carlson, G. A., and Iadecola, C. (2001) A beta-peptides enhance vasoconstriction in cerebral circulation Am. J. Physiol.: Heart Circ. Physiol. 281, H2417-2424
18. de la Torre, J. C. (2000) Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis Neurobiol. Aging 21, 331-342
19. Crawford, F., Soto, C., Suo, Z., Fang, C., Parker, T., Sawar, A., Frangione, B., and Mullan, M. (1998) Alzheimer's beta-amyloid vasoactivity: identification of a novel beta-amyloid conformational intermediate FEBS Lett. 436, 445-448
20. Thomas, T., Sutton, E. T., Hellermann, A., and Price, J. M. (1997) Beta-amyloid-induced coronary artery vasoactivity and endothelial damage J. Cardiovasc. Pharmacol. 30, 517-522
21. Wesson, D. W., Levy, E., Nixon, R. A., and Wilson, D. A. (2010) Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model J. Neurosci. 30, 505-514
22. Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., and Selkoe, D. J. (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration Proc. Natl. Acad. Sci. U.S.A. 108, 5819-5824
23. Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., and Paul, S. M. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model Nat. Neurosci. 5, 452-457
24. Haass, C. and Selkoe, D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide Nat. Rev. Mol. Cell Biol. 8, 101-112
25. Burke, S. N. and Barnes, C. A. (2010) Senescent synapses and hippocampal circuit dynamics Trends Neurosci. 33, 153-161
26. Samuel, W., Masliah, E., Hill, L. R., Butters, N., and Terry, R. (1994) Hippocampal connectivity and Alzheimer's dementia: effects of synapse loss and tangle frequency in a two-component model Neurology 44, 2081-2088
27. Rapp, P. R. and Gallagher, M. (1996) Preserved neuron number in the hippocampus of aged rats with spatial learning deficits Proc. Natl. Acad. Sci. U.S.A. 93, 9926-9930
28. Stranahan, A. M. and Mattson, M. P. (2010) Selective vulnerability of neurons in layer II of the entorhinal cortex during aging and Alzheimer's disease Neural Plast. 2010, 108190
29. Mucke, L., Masliah, E., Yu, G. Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., and McConlogue, L. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation J. Neurosci. 20, 4050-4058
30. Jacobsen, J. S., Wu, C. C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., and Bloom, F. E. (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. U.S.A. 103, 5161-5166
31. Dong, H., Martin, M. V., Chambers, S., and Csernansky, J. G. (2007) Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice J. Comp. Neurol. 500, 311-321
32. Rademakers, R., Cruts, M., and Van Broeckhoven, C. (2003) Genetics of early-onset Alzheimer dementia Sci. World J. 3, 497-519
33. Tanzi, R. E. and Bertram, L. (2001) New frontiers in Alzheimer's disease genetics Neuron 32, 181-184
34. Mayeux. (2003) Epidemiology of Neurodegeneration Annu. Rev. Neurosci. 26, 81-104
35. Van Duijn, C. M., Clayton, D. G., Chandra, V., Fratiglioni, L., Graves, A. B., Heyman, A., Jorm, A. F., Kokmen, E., Kondo, K., and Mortimer, J. A. 1994, Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of case-control studies. EURODEM Risk Factors Research Group Genet. Epidemiol. 11, 539-551
36. Kivipelto, M., Helkala, E. L., Laakso, M. P., Hanninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., and Nissinen, A. (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study BMJ 322, 1447-1451
37. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261, 921-923
38. Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., and Roses, A. D. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 90, 1977-1981
39. Grehan, S., Tse, E., and Taylor, J. M. (2001) Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain J. Neurosci. 21, 812-822
40. Pitas, R. E., B., J., Lee, S. H., Hui, D., and Weisgraber, K. H. (1987) Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain J. Biol. Chem. 6, 63-75
41. Xu, P. T., Schmechel, D., Qiu, H. L., Herbstreith, M., Rothrock-Christian, T., Eyster, M., Roses, A. D., and Gilbert, J. R. (1999) Sialylated human apolipoprotein E (apoEs) is preferentially associated with neuron-enriched cultures from APOE transgenic mice Neurobiol. Dis. 6, 63-75
42. Xu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R. W., and Huang, Y. (2006) Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus J. Neurosci. 26, 4985-4994
43. Mahley, R. W. and Rall, S. C., Jr. (2000) Apolipoprotein E: far more than a lipid transport protein Annu. Rev. Genomics Hum. Genet. 1, 507-537
44. Blacker, D., Haines, J. L., Rodes, L., Terwedow, H., Go, R. C., Harrell, L. E., Perry, R. T., Bassett, S. S., Chase, G., Meyers, D., Albert, M. S., and Tanzi, R. (1997) ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative Neurology 48, 139-147
45. Tierney, M. C., Szalai, J. P., Snow, W. G., Fisher, R. H., Tsuda, T., Chi, H., McLachlan, D. R., and St George-Hyslop, P. H. (1996) A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment Neurology 46, 149-154
46. Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Jr., Rimmler, J. B., Locke, P. A., Conneally, P. M., and Schmader, K. E. 1994, Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease Nat. Genet. 7, 180-184
47. Mahley, R. W., Weisgraber, K. H., and Huang, Y. (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease Proc. Natl. Acad. Sci. U.S.A. 103, 5644-5651
48. LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., and Frail, D. E. (1994) Isoform-specific binding of apolipoprotein E to beta-amyloid J. Biol. Chem. 269, 23403-23406
49. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., and Zlokovic, B. V. (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain J. Clin. Invest. 118, 4002-4013
50. Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., and Zlokovic, B. V. (2007) Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system J. Cereb. Blood Flow Metab. 27, 909-918
51. Ito, S., Ohtsuki, S., Kamiie, J., Nezu, Y., and Terasaki, T. (2007) Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes J. Neurochem. 103, 2482-2490
52. Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., and Paul, S. M. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. U.S.A. 97, 2892-2897
53. Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinisto, L., Halonen, P., and Kontula, K. (1995) Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein New Engl. J. Med. 333, 1242-1247
54. Kinnecom, C., Lev, M. H., Wendell, L., Smith, E. E., Rosand, J., Frosch, M. P., and Greenberg, S. M. (2007) Course of cerebral amyloid angiopathy-related inflammation Neurology 68, 1411-1416
55. Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., and Selkoe, D. J. (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation Neurobiol. Dis. 3, 16-32
56. Hardy, J. and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease Trends Pharmacol. Sci. 12, 383-388
57. Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., and Katzman, R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment Ann. Neurol. 30, 572-580
58. Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., and Davies, P. (1995) Correlations of synaptic and pathological markers with cognition of the elderly Neurobiol. Aging 16, 285-298 discussion 298-304.
59. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I., and Masters, C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann. Neurol. 46, 860-866
60. Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., and Rogers, J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease Am. J. Pathol. 155, 853-862
61. Hardy, J. and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297, 353-356
62. Walsh, D. M. and Selkoe, D. J. (2007) A beta oligomers-a decade of discovery J. Neurochem. 101, 1172-1184
63. Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., and Sabatini, B. L. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway J. Neurosci. 27, 2866-2875
64. Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., and Selkoe, D. (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake Neuron 62, 788-801
65. Glenner, G. G. and Wong, C. W. (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem. Biophys. Res. Commun. 120, 885-890
66. Glenner, G. G. (1989) Amyloid beta protein and the basis for Alzheimer's disease Prog. Clin. Biol. Res. 317, 857-868
67. Ikeda, S., Allsop, D., and Glenner, G. G. (1989) Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. An immunohistochemical study using amyloid beta-protein antibody Lab. Invest. 60, 113-122
68. Goldgaber, D., Lerman, M. I., McBride, O. W., Saffiotti, U., and Gajdusek, D. C. (1987) Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease Science 235, 877-880
69. Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., and Neve, R. L. (1987) Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus Science 235, 880-884
70. St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., and Drachman, D. 1987, The genetic defect causing familial Alzheimer's disease maps on chromosome 21 Science 235, 885-890
71. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K., and Muller-Hill, B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor Nature 325, 733-736
72. Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T., Luyendijk, W., and Frangione, B. (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type Science 248, 1124-1126
73. Selkoe, D. J. (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease Trends Cell Biol. 8, 447-453
74. Bonifacino, J. S. and Traub, L. M. (2003) Signals for sorting of transmembrane proteins to endosomes and lysosomes Annu. Rev. Biochem. 72, 395-447
75. Yamazaki, T., Koo, E. H., and Selkoe, D. J. (1996) Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization J. Cell Sci. 109 (Pt 5) 999-1008
76. Koo, E. H., Squazzo, S. L., Selkoe, D. J., and Koo, C. H. (1996) Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody J. Cell Sci. 109 (Pt 5) 991-998
77. Haass, C., Kaether, C., Thinakaran, G., and Sisodia, S. (2012) Trafficking and proteolytic processing of APP Cold Spring Harbor Perspect. Med. 2, a006270
78. O'Brien, R. J. and Wong, P. C. (2011) Amyloid precursor protein processing and Alzheimer's disease Annu. Rev. Neurosci. 34, 185-204
79. Stokin, G. B. and Goldstein, L. S. (2006) Axonal transport and Alzheimer's disease Annu. Rev. Biochem. 75, 607-627
80. Tienari, P., D. S., B., Ikonen, E., Simons, M., Weidemann, A., and Czech, C., (1996) The beta-amyloid domain is essential for axonal sorting of amyloid precursor protein., EMBO J. 15.
81. Dobson, C. M. (2003) Protein folding and misfolding Nature 426, 884-890
82. Roychaudhuri, R., Yang, M., Hoshi, M. M., and Teplow, D. B. (2009) Amyloid beta-protein assembly and Alzheimer disease J. Biol. Chem. 284, 4749-4753
83. Bernstein, S. L., Dupuis, N. F., Lazo, N. D., Wyttenbach, T., Condron, M. M., Bitan, G., Teplow, D. B., Shea, J. E., Ruotolo, B. T., Robinson, C. V., and Bowers, M. T. (2009) Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease Nat. Chem. 1, 326-331
84. Colletier, J. P., Laganowsky, A., Landau, M., Zhao, M., Soriaga, A. B., Goldschmidt, L., Flot, D., Cascio, D., Sawaya, M. R., and Eisenberg, D. (2011) Molecular basis for amyloid-beta polymorphism Proc. Natl. Acad. Sci. U.S.A. 108, 16938-16943
85. Selkoe, D. J. (2011) Resolving controversies on the path to Alzheimer's therapeutics Nat. Med. 17, 1060-1065
86. Rahimi, F., Shanmugam, A., and Bitan, G. (2008) Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders Curr. Alzheimer Res. 5, 319-341
87. Sakono, M. and Zako, T. (2010) Amyloid oligomers: formation and toxicity of Abeta oligomers FEBS J. 277, 1348-1358
88. Palop, J. J. and Mucke, L. (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks Nat. Neurosci. 13, 812-818
89. Mucke, L. and Selkoe, D. J. (2012) Neurotoxicity of Amyloid beta-Protein: Synaptic and Network Dysfunction Cold Spring Harbor Perspect. Med. 2, a006338
90. Lasagna-Reeves, C. A., Glabe, C. G., and Kayed, R. (2011) Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain J. Biol. Chem. 286, 22122-22130
91. Benilova, I., Karran, E., and De Strooper, B. (2012) The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes Nat. Neurosci. 15, 349-357
92. Caughey, B. and Lansbury, P. T. (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu. Rev. Neurosci. 26, 267-298
93. Glabe, C. G. and Kayed, R. (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis Neurology 66, S74-78
94. Williams, R. (2001) Chemical selection of elements by cells Coord. Chem. Rev. 216, 583-595
95. Laurent, S., Ejtehadi, M. R., Rezaei, M., Kehoe, P. G., and Mahmoudi, M. (2012) Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease RSC Adv. 2, 5008-5033
96. Azhdarzadeh, M. 2013, Serum Multivalent Cationic Pattern: Speculation on the reliable Approach for Detection of Alzheimer's Disease Sci. Rep. 3, 2783 10.1038/srep02782
97. Tottey, S., Harvie, D. R., and Robinson, N. J. (2007) Understanding how cells allocate metals. In Molecular microbiology of heavy metals (Nies, D. H. and Silver, S., Eds.), Springer-Verlag, Berlin, Heidelberg.
98. Chamberlain, R., Reyes, D., Curran, G. L., Marjanska, M., Wengenack, T. M., Poduslo, J. F., Garwood, M., and Jack, C. R., Jr. (2009) Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer's disease Magn. Reson. Med. 61, 1158-1164
99. Zerbi, V., Jansen, D., Dederen, P. J., Veltien, A., Hamans, B., Liu, Y., Heerschap, A., and Kiliaan, A. J. (2012) Microvascular cerebral blood volume changes in aging APP(swe)/PS1 (dE9) AD mouse model: a voxel-wise approach Brain Struc. Funct. 218, 1805-1898
100. Fazil, M., Shadab, Baboota, S., Sahni, J. K., and Ali, J. (2012) Nanotherapeutics for Alzheimer's disease (AD): Past, present and future J. Drug Targeting 20, 97-113
101. Begley, D. J. (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities Pharmacol. Ther. 104, 29-45
102. Gabathuler, R. (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiol. Dis. 37, 48-57
103. Roney, C., Kulkarni, P., Arora, V., Antich, P., Bonte, F., and Wu, A. 2005, Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease J. Controlled Release 108, 193-214
104. Tanifum, E. A., Dasgupta, I., Srivastava, M., Bhavane, R. C., Sun, L., Berridge, J., Pourgarzham, H., Kamath, R., Espinosa, G., Cook, S. C., Eriksen, J. L., and Annapragada, A. (2012) Intravenous delivery of targeted liposomes to amyloid-beta pathology in APP/PSEN1 transgenic mice PloS One 7, e48515
105. Yang, J., Wadghiri, Y. Z., Hoang, D. M., Tsui, W., Sun, Y., Chung, E., Li, Y., Wang, A., de Leon, M., and Wisniewski, T. (2011) Detection of amyloid plaques targeted by USPIO-Abeta1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging NeuroImage 55, 1600-1609
106. Beckmann, N., Gerard, C., Abramowski, D., Cannet, C., and Staufenbiel, M. (2011) Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: application to passive Abeta immunotherapy J. Neurosci. 31, 1023-1031
107. Petiet, A., Santin, M., Bertrand, A., Wiggins, C. J., Petit, F., Houitte, D., Hantraye, P., Benavides, J., Debeir, T., Rooney, T., and Dhenain, M. (2012) Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice Neurobiol. Aging 33, 1533-1544
108. Poduslo, J. F., Wengenack, T. M., Curran, G. L., Wisniewski, T., Sigurdsson, E. M., Macura, S. I., Borowski, B. J., and Jack, C. R., Jr. (2002) Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging Neurobiol. Dis. 11, 315-329
109. Sillerud, L. O., Solberg, N. O., Chamberlain, R., Orlando, R. A., Heidrich, J. E., Brown, D. C., Brady, C. I., Vander Jagt, T. A., Garwood, M., and Vander Jagt, D. L. (2013) SPION-Enhanced Magnetic Resonance Imaging of Alzheimer's Disease Plaques in AbetaPP/PS-1 Transgenic Mouse Brain J. Alzheimer's Dis. 34, 349-365
110. Cai, W. and Chen, X. (2007) Nanoplatforms for targeted molecular imaging in living subjects Small 3, 1840-1854
111. Cao, C. Y., Shen, Y. Y., Wang, J. D., Li, L., and Liang, G. L. (2013) Controlled intracellular self-assembly of gadolinium nanoparticles as smart molecular MR contrast agents Sci. Rep. 3, 1024
112. Kanal, E. (2012) Gadolinium-based magnetic resonance contrast agents for neuroradiology: an overview Magn. Reson. Imaging Clin. North Am. 20, 625-631
113. Othman, M., Desmaele, D., Couvreur, P., Vander Elst, L., Laurent, S., Muller, R. N., Bourgaux, C., Morvan, E., Pouget, T., Lepetre-Mouelhi, S., Durand, P., and Gref, R. (2011) Synthesis and physicochemical characterization of new squalenoyl amphiphilic gadolinium complexes as nanoparticle contrast agents Org. Biomol. Chem. 9, 4367-4386
114. Laurent, S., Vander Elst, L., Fu, Y., and Muller, R. N. (2004) Synthesis and physicochemical characterization of Gd-DTPA-B(sLex)A, a new MRI contrast agent targeted to inflammation Bioconjugate Chem. 15, 99-103
115. Amiri, H., Bustamante, R., Millan, A., Silva, N. J., Pinol, R., Gabilondo, L., Palacio, F., Arosio, P., Corti, M., and Lascialfari, A. (2011) Magnetic and relaxation properties of multifunctional polymer-based nanostructured bioferrofluids as MRI contrast agents Magn. Reson. Med. 66, 1715-1721
116. Amiri, H., Mahmoudi, M., and Lascialfari, A. (2011) Superparamagnetic colloidal nanocrystal clusters coated with polyethylene glycol fumarate: a possible novel theranostic agent Nanoscale 3, 1022-1030
117. Hosseini, F., P., A., Adeli, M., Amiri, H., Lascialfari, A., Orsini, F., Doschak, M. R., and Mahmoudi, M. (2013) Synthesis of pseudopolyrotaxanes-coated Superparamagnetic Iron Oxide Nanoparticles as new MRI contrast agent Colloids Surf., B 652-657
118. Wang, Y. X. (2011) Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application Quant. Imaging Med. Surg. 1, 35-40
119. Higuchi, M., Iwata, N., Matsuba, Y., Sato, K., Sasamoto, K., and Saido, T. C. (2005) 19F and 1H MRI detection of amyloid beta plaques in vivo Nat. Neurosci. 8, 527-533
120. Yanagisawa, D., Amatsubo, T., Morikawa, S., Taguchi, H., Urushitani, M., Shirai, N., Hirao, K., Shiino, A., Inubushi, T., and Tooyama, I. (2011) In vivo detection of amyloid beta deposition using (1)(9)F magnetic resonance imaging with a (1)(9)F-containing curcumin derivative in a mouse model of Alzheimer's disease Neuroscience 184, 120-127
121. Houshang Amiri, M. S., Andor Veltein, Mark J., van Uden, I., Jolanda, M., and de Vries, Arend Heerschap. (2013) Cell Tracking by 19F MRI:Technical Aspects and Challenges towards Clinical Applications. Submitted for publication.
122. Krol, S., Macrez, R., Docagne, F., Defer, G., Laurent, S., Rahman, M., Hajipour, M. J., Kehoe, P. G., and Mahmoudi, M. (2013) Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier Chem. Rev. 113, 1877-1903
123. Mahmoudi, M., Quinlan-Pluck, F., Monopoli, M. P., Sheibani, S., Vali, H., Dawson, K. A., and Lynch, I. (2013) Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid beta protein fibrillation in solution ACS Chem. Neurosci. 4, 475-485
124. Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Dawson, K. A., and Linse, S. (2010) Dual effect of amino modified polystyrene nanoparticles on amyloid beta protein fibrillation ACS Chem. Neurosci. 1, 279-287
125. Amiri, H., Bordonali, L., Lascialfari, A., Wan, S., Monopoli, M. P., Lynch, I., Laurent, S., and Mahmoudi, M. (2013) Protein corona affects the relaxivity and MRI contrast efficiency of magnetic nanoparticles Nanoscale 5, 8656-8665
126. Dorota Walczyk, B. F., Monopoli, M. P., Lynch, I., and Dawson, K. A. (2010) What the cell ″sees″ in bionanoscience J. Am. Chem. Soc. 5761-5768
127. Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Bombelli, F. B., and Dawson, K. A. (2011) Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles J. Am. Chem. Soc. 133, 2525-2534
128. Mahmoudi, M., Lynch, I., Ejtehadi, M. R., Monopoli, M. P., Bombelli, F. B., and Laurent, S. (2011) Protein-nanoparticle interactions: opportunities and challenges Chem. Rev. 111, 5610-5637
129. Lesniak, A., Fenaroli, F., Monopoli, M. P., Aberg, C., Dawson, K. A., and Salvati, A. (2012) Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells ACS Nano 6, 5845-5857
130. Mahmoudi, M., Monopoli, M. P., Rezaei, M., Lynch, I., Bertoli, F., McManus, J. J., and Dawson, K. A. (2013) The protein corona mediates the impact of nanomaterials and slows amyloid beta fibrillation ChemBioChem 14, 568-572
131. Mahmoudi, M., Akhavan, O., Ghavami, M., Rezaee, F., and Ghiasi, S. M. (2012) Graphene oxide strongly inhibits amyloid beta fibrillation Nanoscale 4, 7322-7325
132. Mahmoudi, M., Abdelmonem, A. M., Behzadi, S., Clement, J. H., Dutz, S., Ejtehadi, M. R., Hartmann, R., Kantner, K., Linne, U., Maffre, P., Metzler, S., Moghadam, M. K., Pfeiffer, C., Rezaei, M., Ruiz-Lozano, P., Serpooshan, V., Shokrgozar, M. A., Nienhaus, G. U., and Parak, W. J. (2013) Temperature: The "Ignored" Factor at the NanoBio Interface ACS Nano 7, 6555-6562
133. Ghavami, M., Rezaei, M., Ejtehadi, R., Lotfi, M., Shokrgozar, M. A., Abd Emamy, B., Raush, J., and Mahmoudi, M. (2013) Physiological temperature has a crucial role in amyloid beta in the absence and presence of hydrophobic and hydrophilic nanoparticles ACS Chem. Neurosci. 4, 375-378
134. Mahmoudi, M., Laurent, S., Shokrgozar, M. A., and Hosseinkhani, M. (2011) Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical properties of nanoparticles ACS Nano 5, 7263-7276
135. Laurent, S., Burtea, C., Thirifays, C., Rezaee, F., and Mahmoudi, M. (2013) Significance of cell "observer" and protein source in nanobiosciences J. Colloid Interface Sci. 392, 431-445
136. Rauch, J., Kolch, W., and Mahmoudi, M. (2012) Cell type-specific activation of AKT and ERK signaling pathways by small negatively-charged magnetic nanoparticles Sci. Rep. 2, 868
137. Mahmoudi, M., Saeedi-Eslami, S. N., Shokrgozar, M. A., Azadmanesh, K., Hassanlou, M., Kalhor, H. R., Burtea, C., Rothen-Rutishauser, B., Laurent, S., Sheibani, S., and Vali, H. (2012) Cell "vision": complementary factor of protein corona in nanotoxicology Nanoscale 4, 5461-5468
138. Laurent, S., Burtea, C., Thirifays, C., Hafeli, U. O., and Mahmoudi, M. (2012) Crucial ignored parameters on nanotoxicology: the importance of toxicity assay modifications and "cell vision" PloS one 7, e29997
139. Mahmoudi, M., Hosseinkhani, H., Hosseinkhani, M., Boutry, S., Simchi, A., Journeay, W. S., Subramani, K., and Laurent, S. (2011) Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine Chem. Rev. 111, 253-280
140. Mahmoudi, M., M., A., and Stroeve, P. (2010) Surface Architecture of Superparamagnetic Iron Oxide Nanoparticles for Application in Drug Delivery and Their Biological Response: A Review Int. J. Biomed. Nanosci. Nanotechnol. 164-201
141. Mahmoudi, M., Shokrgozar, M. A., Sardari, S., Moghadam, M. K., Vali, H., Laurent, S., and Stroeve, P. (2011) Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles Nanoscale 3, 1127-1138
142. Mahmoudi, M., S., A., and Imani, M. (2010) Recent Advances in Surface Engineering of Superparamagnetic Iron Oxide Nanoparticles for Biomedical Applications J. Iran. Chem. Soc. 7, S1-S27
143. Nighoghossian, N., Wiart, M., Cakmak, S., Berthezene, Y., Derex, L., Cho, T. H., Nemoz, C., Chapuis, F., Tisserand, G. L., Pialat, J. B., Trouillas, P., Froment, J. C., and Hermier, M. (2007) Inflammatory response after ischemic stroke: a USPIO-enhanced MRI study in patients Stroke 38, 303-307
144. Saleh, A., Schroeter, M., Ringelstein, A., Hartung, H. P., Siebler, M., Modder, U., and Jander, S. (2007) Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke Stroke 38, 2733-2737
145. Dousset, V., Brochet, B., Deloire, M. S., Lagoarde, L., Barroso, B., Caille, J. M., and Petry, K. G. (2006) MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium AJNR Am. J. Neuroradiol. 27, 1000-1005
146. Tourdias, T., Roggerone, S., Filippi, M., Kanagaki, M., Rovaris, M., Miller, D. H., Petry, K. G., Brochet, B., Pruvo, J. P., Radue, E. W., and Dousset, V. (2012) Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging Radiology 264, 225-233
147. Mahmoudi, M., Sahraian, M. A., Shokrgozar, M. A., and Laurent, S. (2011) Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis ACS Chem. Neurosci. 2, 118-140
148. Mahmoudi, M., Sant, S., Wang, B., Laurent, S., and Sen, T. (2011) Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy Adv. Drug Delivery Rev. 63, 24-46
149. Mahmoudi, M, Stroeve, P., Milani, A. S., and Arbab, A. S. (2010) Superparamagnetic iron oxide nanoparticles for biomedical applications, Nova Science Publishers, Hauppauge, NY.
150. Brambilla, D., Verpillot, R., Le Droumaguet, B., Nicolas, J., Taverna, M., Kona, J., Lettiero, B., Hashemi, S. H., De Kimpe, L., Canovi, M., Gobbi, M., Nicolas, V., Scheper, W., Moghimi, S. M., Tvaroska, I., Couvreur, P., and Andrieux, K. (2012) PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease ACS Nano 6, 5897-5908
151. Skaat, H., Belfort, G., and Margel, S. (2009) Synthesis and characterization of fluorinated magnetic core-shell nanoparticles for inhibition of insulin amyloid fibril formation Nanotechnology 20, 225106
152. Skaat, H. and Margel, S. (2009) Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-beta fibrils detection and removal by a magnetic field Biochem. Biophys. Res. Commun. 386, 645-649
153. Skaat, H., Sorci, M., Belfort, G., and Margel, S. (2009) Effect of maghemite nanoparticles on insulin amyloid fibril formation: selective labeling, kinetics, and fibril removal by a magnetic field J. Biomed. Mater. Res., Part A 91, 342-351
154. Andersson, B. V., Skoglund, C., Uvdal, K., and Solin, N. (2012) Preparation of amyloid-like fibrils containing magnetic iron oxide nanoparticles: effect of protein aggregation on proton relaxivity Biochem. Biophys. Res. Commun. 419, 682-686
155. 4 magnetic nanoparticles on lysozyme amyloid aggregation Nanotechnology 21, 065103
156. Mahmoudi, M., Hofmann, H., Rothen-Rutishauser, B., and Petri-Fink, A. (2012) Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles Chem. Rev. 112, 2323-2338
157. Conti, B. and Hansen, M. (2013) A cool way to live long Cell 152, 671-672
158. Xiao, R., Zhang, B., Dong, Y., Gong, J., Xu, T., Liu, J., and Xu, X. Z. (2013) A Genetic Program Promotes C. elegans Longevity at Cold Temperatures via a Thermosensitive TRP Channel Cell 152, 806-817
159. Vinters, H. V., Natte, R., Maat-Schieman, M. L., van Duinen, S. G., Hegeman-Kleinn, I., Welling-Graafland, C., Haan, J., and Roos, R. A. (1998) Secondary microvascular degeneration in amyloid angiopathy of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D) Acta Neuropathol. 95, 235-244
160. El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., and Luster, A. D. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease Nat. Med. 13, 432-438
161. Hickman, S. E. and El Khoury, J. (2010) Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease CNS Neurol. Disord.: Drug Targets 9, 168-173
162. Deng, Z. J., Liang, M., Monteiro, M., Toth, I., and Minchin, R. F. (2011) Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation Nature Nanotechnol. 6, 39-44
163. Ahn, H. J., Zamolodchikov, D., Cortes-Canteli, M., Norris, E. H., Glickman, J. F., and Strickland, S. (2010) Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization Proc. Natl. Acad. Sci. U.S.A. 107, 21812-21817